Pathogen inactivation technologies for cellular blood components: An update

Transfusion Medicine and Hemotherapy

Volumn 41, Issue 4, 2014, Pages 309-325

  Schlenke, Peter ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Bacteria; Blood safety; Chikungunya virus; Dengue virus; Hemovigilance; Pathogen inactivation; Platelet concentrates; Protozoa; Randomized clinical trial; Red blood cells; West Nile virus

Indexed keywords

BLOOD; BLOOD SAFETY; CHIKUNGUNYA ALPHAVIRUS; CLINICAL EVALUATION; DENGUE VIRUS; ERYTHROCYTE; HUMAN; NONHUMAN; PATHOGEN INACTIVATION TECHNOLOGY; PATHOGEN REDUCTION SYSTEM; PLASMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; TECHNOLOGY; THROMBOCYTE; TOXICOLOGY; VIRUS INACTIVATION; VIRUS INFECTION; WEST NILE FLAVIVIRUS;

EID: 84906559343     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000365646     Document Type: Review

References (134)

1. Lindholm PF, Annen K, Ramsey G: Approaches to minimize infection risk in blood banking and transfusion practice. Infect Disord Drug Targets 2011; 11:45-56.
2. Dodd RY: Emerging pathogens and their implications for the blood supply and transfusion transmitted infections. Br J Hematol 2012;159:135-142.
3. Spahn DR, Goodnough LT: Alternatives to blood transfusion. Lancet 2013;381:1855-1865.
4. Engelbrecht S, Wood EM, Cole-Sinclair MF: Clinical transfusion practice update: haemovigilance, complications, patient blood management and national standards. Med J Aust 2013;199:397-401.
5. Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ; German Red Cross NAT Study Group: Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 2008;48:1558-1566.
6. Nubling CM, Heiden M, Chudy M, Kress J, Seitz R, Keller-Stanislawski B, Funk MB: Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions. Transfusion 2009;49:1850-1859.
7. Morel P: Ten years of nucleic acid testing: lessons and prospects (in French). Transfus Clin Biol 2011; 18:133-139.
8. Roth WK, Busch MP, Schuller A, Ismay S, Cheng A, Seed CR, Jungbauer C, Minsk PM, Sondag- Thull D, Wendel S, Levi JE, Fearon M, Delage G, Xie Y, Jukic I, Turek P, Ullum H, Tefanova V, Tilk M, Reimal R, Castren J, Naukkarinen M, Assal A, Jork C, Hourfar MK, Michel P, Offergeld R, Pichl L, Schmidt M, Schottstedt V, Seifried E, Wagner F, Weber-Schehl M, Politis C, Lin CK, Tsoi WC, O'Riordan J, Gottreich A, Shinar E, Yahalom V, Velati C, Satake M, Sanad N, Sisene I, Bon AH, Koppelmann M, Flanagan P, Flesland O, Brojer E, L towska M, Nascimento F, Zhiburt E, Chua SS, Teo D, Stezinar SL, Vermeulen M, Reddy R, Park Q, Castro E, Eiras A, Gonzales Fraile I, Torres P, Ekermo B, Niederhauser C, Chen H, Oota S, Brant LJ, Eglin R, Jarvis L, Mohabir L, Brodsky J, Foster G, Jennings C, Notari E, Stramer S, Kessler D, Hillyer C, Kamel H, Katz L, Taylor C, Panzer S, Reesink HW: International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang 2012;102:82-90
9. Schrezenmeier H, Walther-Wenke G, Muller TH, Weinauer F, Younis A, Holland-Letz T, Geis G, Asmus J, Bauerfeind U, Burkhart J, Deitenbeck R, Forstemann E, Gebauer W, Hochsmann B, Karakassopoulos A, Liebscher UM, Sanger W, Schmidt M, Schunter F, Sireis W, Seifried E: Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 2007;47:644-652.
10. Funk MB, Lohmann A, Guenay S, Henseler O, Heiden M, Hanschmann KM, Keller-Stanislawski B: Transfusion-transmitted bacterial infections - haemovigilance data of German blood establishments (1997-2010). Transfus Med Hemother 2011; 38:266-271.
11. Rebulla P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni G, Barbui T, Mandelli F, Sirchia G: The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 1997;337:1870-1875.
12. Slichter SJ, Kaufman RM, Assmann SF, Mc- Cullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S: Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010;362:600-613.
13. Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, Mahlknecht U, Ho A, Schaich M, Kramer M, Kaufmann M, Leimer L, Schwerdtfeger R, Conradi R, Dolken G, Klenner A, Hanel M, Herbst R, Junghanss C, Ehninger G; Study Alliance Leukemia: Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012;380:1309-1316.
14. Myhre BA, McRuer D: Human error-a significant cause of transfusion mortality. Transfusion 2000; 40:879-885.
15. Muller MH: Increasing safety by implementing optimized team interaction - experiences of the aviation industry; in Scharf RE (ed): Progress and Challenges in Transfusion Medicine, Hemostasis and Hemotherapy. Freiburg, Karger, 2008, pp1-14.
16. Leape LL: Errors in medicine. Clin Chim Acta 2009;404:2-5.
17. Elhence P, Veena S, Sharma RK, Chaudhary RK: Root cause analysis of transfusion error: identifying causes to implement changes. Transfusion 2010; 50:2772-2777.
18. Dunstan RA, Seed CR, Keller AJ: Emerging viral threats to the Australian blood supply. Aust N Z Public Health 2008;32:354-360.
19. Fournier-Wirth C, Jaffrezic-Renault N, Coste J: Detection of blood-transmissible agents: can screening be miniaturized? Transfusion 2010;50:2032-2045.
20. Gallagher LM, Ganz PR, Yang H, Kessler DA, O'Brien SF, Custer BS, Busch MP, Dodd RY, Stramer SL, Walderhaug MO, Forshee RA, Williams AE, Epstein JS, Anderson SA: Advancing risk assessment for emerging infectious diseases for blood and blood products: proceedings of a public workshop. Transfusion 2013;53:455-463.
21. Paty MC: The expansion of vector-borne diseases and the implications for blood transfusion safety: the case of West Nile Virus, dengue and chikungunya (in French). Transfus Clin Biol 2013;20:165-173.
22. Bryant BJ, Klein HG: Pathogen inactivation: the definitive safeguard for the blood supply. Arch Pathol Lab Med 2007;131:719-733.
23. Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, Robitaille N, Sivilotti ML, Smaill F: Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007;47:2338-2347.
24. Prowse CV: Component pathogen inactivation: a critical review. Vox Sang 2013;104:183-199
25. Seltsam A, Muller TH: Update on the use of pathogen- reduced human plasma and platelet concentrates. Br J Hematol 2013;162:442-454.
26. Kleinman S, Reed W, Stassinopoulos A: A patientoriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States. Transfusion 2013;53: 1603-1618.
27. Gallo RC, Sarin PS, Gelmann EP, Robert-Guroff M, Richardson E, Kalyanaraman VS, Mann D, Sidhu GD, Stahl RE, Zolla-Pazner S, Leibowitch J, Popovic M: Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983;220:865-8657.
28. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220: 868-671.
29. Lanteri MC, Busch MP: Dengue in the context of 'safe blood' and global epidemiology: to screen or not to screen? Transfusion 2012;52:1634-1639.
30. Teo D, Ng LC, Lam S: Is dengue a threat to the blood supply? Transfus Med 2009;19:66-77.
31. Rogers DJ, Suk JE, Semenza JC: Using global maps to predict the risk of dengue in Europe. Acta Trop 2014;129:1-14.
32. Kampen H, Kronefeld M, Zielke D, Werner D: Further specimens of the Asian tiger mosquito Aedes albopictus (Diptera, Culicidae) trapped in southwest Germany. Parasitol Res 2013;112:905-907.
33. Chuang V, Wong TY, Leung YH, Ma E, Law YL, Tsang O, Chan KM, Tsang I, Que TL, Yung R, Liu SH: Review of dengue fever cases in Hong Kong during 1998 to 2005. Hong Kong Med J 2008;14: 170-177.
34. Tambyah PA, Koay ES, Poon ML, Lin RV, Ong BK; Transfusion-Transmitted Dengue Infection Study Group: Dengue hemorrhagic fever transmitted by blood transfusion. N Engl J Med 2008;359: 1526-1527.
35. Dias LL, Amarilla AA, Poloni TR, Covas DT, Aquino VH, Figueiredo LT: Detection of dengue virus in sera of Brazilian blood donors. Transfusion 2012;52:1667-1671.
36. Petersen LR, Tomashek KM, Biggerstaff BJ: Estimated prevalence of dengue viremia in Puerto Rican blood donations, 1995 through 2010. Transfusion 2012;52:1647-1651.
37. Fischer D, Thomas SM, Suk JE, Sudre B, Hess A, Tjaden NB, Beierkuhnlein C, Semenza JC: Climate change effects on Chikungunya transmission in Europe: geospatial analysis of vector's climatic suitability and virus' temperature requirements. Int J Health Geogr 2013;12:51.
38. Charrel RN, de Lamballerie,X, Raoult D: Chikungunya outbreaks - the globalization of vectorborne diseases. N Engl J Med 2007;356:769-771.
39. Renault P, Solet JL, Sissoko D, Balleydier E, Larrieu S, Filleul L, Lassalle C, Thiria J, Rachou E, de Valk H, Ilef D, Ledrans M, Quatresous I, Quenel P, Pierre V: A major epidemic of chikungunya virus infection on Reunion Island, France, 2005-2006. Am J Trop Med Hyg 2007;77:727-731.
40. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S: A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 2007;3:201
41. Rasongles P, Angelini-Tibert MF, Simon P, Currie C, Isola H, Kientz D, Slaedts M, Jacquet M, Sundin D, Lin L, Corash L, Cazenave JP: Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Reunion. Transfusion 2009;49:1083-1091.
42. Liumbruno GM, Calteri D, Petropulacos K, Mattivi A, Po C, Macini P, Tomasini I, Zucchelli P, Silvestri AR, Sambri V, Pupella S, Catalano L, Piccinini V, Calizzani G, Grazzini G: The chikungunya epidemic in Italy and its repercussion on the blood system. Blood Transfus 2008;6:199-210.
43. Rezza G, Nicoletti L, Angelini R, Romi R, Finarelli AC, Panning M, Cordioli P, Fortuna C, Boros S, Magurano F, Silvi G, Angelini P, Dottori M, Ciufolini MG, Majori GC, Cassone A; CHIKV study group: Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet 2007;370:1840-1846.
44. Petersen LR, Stramer SL, Powers AM: Chikungunya virus: possible impact on transfusion medicine. Transfus Med Rev 2010;24:15-21.
45. Nash D, Mostashari F, Fine A, Miller J, O'Leary D, Murray K, Huang A, Rosenberg A, Greenberg A, Sherman M, Wong S, Layton M; 1999 West Nile Outbreak Response Working Group: The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 2001;344:1807-1814.
46. Pealer LN, Marfin AA, Petersen LR, Lanciotti RS, Page PL, Stramer SL, Stobierski MG, Signs K, Newman B, Kapoor H, Goodman JL, Chamberland ME; West Nile Virus Transmission Investigation Team: Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003;349:1236-1245.
47. Lai L, Lee TH, Tobler L, Wen L, Shi P, Alexander J, Ewing H, Busch M: Relative distribution of West Nile virus RNA in blood compartments: implications for blood donor nucleic acid amplification technology screening. Transfusion 2012;52:2012:447-454.
48. Montgomery SP, Brown JA, Kuehnert M, Smith TL, Crall N, Lanciotti RS, Macedo de Oliveira A, Boo T, Marfin AA; 2003 West Nile Virus Transfusion- Associated Transmission Investigation Team: Transfusion-associated transmission of West Nile virus, United States 2003 through 2005. Transfusion 2006;46:2038-2046.
49. Francis RO, Strauss D, Williams JD, Whaley S, Shaz BH: West Nile virus infection in blood donors in the New York City area during the 2010 seasonal epidemic. Transfusion 2012;52:2664-2670.
50. Pybus OG, Suchard MA, Lemey P, Bernardin FJ, Rambaut A, Crawford FW, Gray RR, Arinaminpathy N, Stramer SL, Busch MP, Delwart EL: Unifying the spatial epidemiology and molecular evolution of emerging epidemics. Proc Natl Acad Sci U S A 2012;109:15066-15071.
51. Barzon L, Pacenti M, Cusinato R, Cattai M, Franchin E, Pagni S, Martello T, Bressan S, Squarzon L, Cattelan A, Pellizzer G, Scotton P, Beltrame A, Gobbi F, Bisoffi Z, Russo F, Palu G: Human cases of West Nile virus infection in north-eastern Italy, 15 June to 15 November 2010. Euro Surveill 2011;16:pii19959.
52. Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, Wilson M: Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med 2011;155:509-519.
53. Leiby DA: Transfusion-associated babesiosis: shouldn't we be ticked off? Ann Intern Med 2011; 155:556-557.
54. Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, van Amerongen G, van Riel D, Laman JD, de Jong T, van Doornum G, Lim W, Ling AE, Chan PK, Tam JS, Zambon MC, Gopal R, Drosten C, van der Werf S, Escriou N, Manuguerra JC, Stohr K, Peiris JS, Osterhaus AD: Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003;362:263-270.
55. Likos AM, Kelvin DJ, Cameron CM, Rowe T, Kuehnert MJ, Norris PJ; National Heart, Lung, Blood Institute Retrovirus Epidemiology Donor Study-II (REDS-II): Influenza viremia and the potential for blood-borne transmission. Transfusion 2007;47:1080-1088.
56. Qi X, Qian YH, Bao CJ, Guo XL, Cui LB, Tang FY, Ji H, Huang Y, Cai PQ, Lu B, Xu K, Shi C, Zhu FC, Zhou MH, Wang H: Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013:epidemiological investigation. BMJ 2013;347:f4752. doi: 10.1136/ bmj.fd4752.
57. Schlenke P, Hervig T, Isola H, Wiesel ML, Kientz D, Pinkoski L, Singh Y, Lin L, Corash L, Cazenave JP: Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers. Transfusion 2008;48:697-705.
58. Hornsey VS, Drummond O, Morrison A, McMillan L, MacGregor IR, Prowse CV: Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins. Transfusion 2009;49:2176-2172.
59. Irsch J, Lin L. Pathogen Inactivation of platelet and plasma blood components for transfusion using the INTERCEPT Blood SystemTM. Transfus Med Hemother 2011;38:19-31.
60. Marschner S, Goodrich R. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011;38:8-18.
61. Feys HB, Van Aelst B, Devreese K, Devloo R, Coene J, Vanderkerckhoves P, Compermolle V: Oxygen removal during pathogen inactivation with riboflavin and UV light preserves protein function in plasma for transfusion. Vox Sang 2014;106:307-315.
62. Mohr H, Steil L, Gravemann U, Thiele T, Hammer E, Greinacher A, Muller TH, Volker U: A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009;49:2612-2624.
63. Mohr H, Gravemann U, Bayer A, Muller TH: Sterilization of platelet concentrates at production scale by irradiation with short-wave ultraviolet light. Transfusion 2009;49:1956-1963.
64. Seltsam A, Muller TH: UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011;38:43-54.
65. Seghatchian J, Struff WG, Reichenberg S. Main properties of the THERAFLEX MB-plasma system for pathogen reduction. Transfus Med Hemother 2011;38:55-64.
66. Pohler P, Lehmann J, Veneruso V, Tomm J, von Bergen M, Lambrecht B, Kohn B, Weingart C, Muller TH, Seltsam A: Evaluation of the tolerability and immunogenicity of ultraviolet C-irradiated autologous platelets in a dog model. Transfusion 2012;52:2414-2426.
67. Ciaravino V, McCullough T, Cimino G: The role of toxicology assessment in transfusion medicine. Transfusion 2003;43:1481-1492.
68. Ciaravino V, Hanover J, Lin L, Sullivan T, Corash L: Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats. Transfusion 2009;49:985-994.
69. Reddy HL, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich RP: Toxicity testing of a novel riboflavin- based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev 2008;22:133-153.
70. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP: Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44:877-885.
71. Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR, Dodd RY: Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009;49(suppl 2): 1S-29S.
72. Goodrich RP, Gilmour D, Hovenga N, Keil SH: A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009;49:1205-1216.
73. Dupuis K, Arnold DJ, Sawyer L: High titers of dengue virus in platelet concentrates are inactivated by amotosalen and UVA light (abstract). Transfusion 2012;52(3 suppl):225A.
74. Arslan O, Ozukul A, Dupuis K, Sahin F, Stassinopoulos A: Inactivation of Crimean-Congo hemorrhagic fever virus (CCHFV) in full units of human plasma using amotosalen and UVA. Vox Sang 2013;105(suppl 1):155.
75. Castro E, Gonzalez LM, Rubio R, Girones N, Montero E: The efficacy of UVC pathogen inactivation on the reduction of Babesia divergens in buffy coat derived platelets. Vox Sang 2013;105 (suppl 1):134.
76. Castro E, Marin-Garcia P, Bautista JM, Montero E, Runio JM: The efficacy of UVC pathogen inactivation on the reduction of Plasmodium falciparum in buffy coat derived platelets. Vox Sang 2013; 105(suppl 1):133.
77. Gravemann U, Schmidt JP, Tolksdorf F, Sumian C, Muller TH, Bauer G, Biczysko S, Keppler O, Seltsam A, Rabenau HF: Influenza A virus H3N2 is efficiently inactivated by the Theraflex UV-Platelets System. Vox Sang 2013;105(suppl 1):134.
78. Vanlandingham DL, Keil SD, Horne KM, Pyles R, Goodrich RP, Higgs S: Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system. Transfusion 2013;53:284-290.
79. Steinmann E, Gravemann U, Friesland M, Doerrbecker J, Muller TH, Pietschmann T, Seltsam A: Two pathogen reduction technologies - methylene blue plus light and shortwave ultraviolet light - effectively inactivate hepatitis C virus in blood products. Transfusion 2013;53:1010-1018.
80. Stormer M, Arroyo A, Brachert J, Carrero H, Devine D, Epstein JS, Gabriel C, Gelber C, Goodrich R, Hanschmann KM, Heath DG, Jacobs MR, Keil S, de Korte D, Lambrecht B, lee CK, Marcelis J, Marschner S, McDonald C, McGuane S, McKee M, Muller TH, Muthivhi T, Pettersson A, Radziwon P, Ramirez-Arcos S, Reesink HW, Rojo J, Rood I, Schmidt M, Schneider CK, Seifried E, Sicker U, Wendel S, Wood EM, Yomtovian RA, Montag T: Establishment of the first international repository for transfusion-relevant bacteria reference strains: ISBT working party transfusion-transmitted infectious diseases (WP-TTID), subgroup bacteria. Vox Sang 2012;102:22-31.
81. Bakkour S, Chafets DM, Wen L, Montalvo L, Busch MP, Lee T: Evaluation of Mirasol® treatment of parvovirus B19 in plasma using real-time PCR inhibition assays. Transfusion 2012;52(suppl): 224A-225A.
82. Snyder E, Raife T, Lin L, Cimino G, Metzel P, Rheinschmidt M, Baril L, Davis K, Buchholz DH, Corash L, Conlan MG: Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 2004;44:1732-1740.
83. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP: Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005;45:1335-1341.
84. Bashir S, Cookson P, Wiltshire M, Hawkins L, Sonoda L, Thomas S, Seltsam A, Tolksdorf F, Williamson LM, Cardigan R: Pathogen inactivation of platelets using ultraviolet C light: effect on in vitro function and recovery and survival of platelets. Transfusion 2013;53:990-1000.
85. Thiele T, Pohler P, Kohlmann T, Sumnig A, Aurich K, Selleng K, Westphal A, Muller T, Seltsam A, Greinacher A: Open phase I clinical trial on safety and tolerance of autologous UVC-treated single donor platelet concentrates in healthy volunteers - dose escalation study (abstract). Transfus Med Hemother 2013;40(suppl 1):50.
86. van Rhenen D, Gulliksson H, Cazenave J-P, Pamphilon D, Ljungman P, Klueter H, Vermeij H, Kappers-Klune M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L: Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-2433.
87. McCullough J, Vesole D, Benjamin R, Slichter S, Pineda A, Snyder E, Stadtmauer E, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard IVF, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz D, Conlan M: Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004;104:1534-1541.
88. Janetzko K, Cazenave JP, Kluter H, Kientz D, Michel M, Beris P, Lioure B, Hastka J, Marblie S, Mayaudon V, Lin L, Lin JS, Conlan MG, Flament J: Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005;45:1443-1452.
89. Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus LC, de Greef GE, Luten M, Huijgens PC, Brand A, van Rhenen DJ; Dutch-Belgian HOVON cooperative group: Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Hematol 2010;150:209-217.
90. Lozano M, Knutson F, Tardivel R, Cid J, Maymo RM, Lof H, Roddie H, Pelly J, Docherty A, Sherman C, Lin L, Propst M, Corash L, Prowse C: A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Hematol 2011;153:393-401.
91. Slichter SJ, Raife TJ, Davis K, Rheinschmidt M, Buchholz DH, Corash L, Conlan MG: Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 2006;46:731-740.
92. Simonsen AC, Johansson PI, Conlan MG, Jacquet M, Lin JS, Junge K, Lin L, Sørensen H, Borregaard N, Flament J: Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study. Transfusion 2006;46:424-433.
93. Vamvakas EC: Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets. Transfusion 2011;51:1058-1071.
94. Cid J, Escolar G, Lozano M: Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials. Vox Sang 2012;103:322-330.
95. Corash L, Sherman CD: Evaluation of platelet transfusion clinical trials. Br J Hematol 2011;153: 529-531.
96. Kerkhoffs JLH: Response to Corash and Sherman. Br J Hematol 2011;153:531-532.
97. Sherman CD, Corash LM: Assessment of hemostasis in platelet transfusion clinical trials with differential follow-up. Vox Sang 2012;103:179.
98. Ypma PF, Kerkhoffs JL, van Hilten JA, Middelburg RA, Coccoris M, Zwaginga JJ, Beckers EM, Fijnheer R, van der Meer PF, Brand A: The observation of bleeding complications in haematooncological patients: stringent watching, relevant reporting. Transfus Med 2012;22:426-431.
99. Webert KE, Arnold DM, Lui Y, Carruthers J, Arnold E, Heddle NM: A new tool to assess bleeding severity in patients with chemotherapy-induced thrombocytopenia. Transfusion 2012;52:2466-2474.
100. Cazenave JP, Isola H, Waller C, Mendel I, Kientz D, Laforet M, Raidot JP, Kandel G, Wiesel ML, Corash L: Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011;51:622-629.
101. Vamvakas EC: Meta-analysis of the studies of bleeding complications of platelets pathogenreduced with the Intercept system. Vox Sang 2012;102:302-316.
102. Murphy S, Snyder E, Cable R, Slichter SJ, Strauss RG, McCullough J, Lin JS, Corash L, Conlan MG; SPRINT Study Group: Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion 2006;46:24-33.
103. Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin JS, Corash L, Conlan MG; SPRINT Study Group: Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005;45:1864-1875.
104. Infanti L, Stebler C, Job S, Ruesch M, Gratwohl A, Irsch J, Lin L, Buser A: Pathogen-inactivation of platelet components with the INTERCEPT Blood SystemTM: a cohort study. Transfus Apher Sci 2011;45:175-181.
105. Schlenke P, Hagenah W, Irsch J, Sundin D, Corash L, Lin L, Kirchner H, Wagner T: Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients. Ann Hematol 2011; 90:1457-1465.
106. Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat M, Barbolla L, Tardivel R, Defoin L, Waller C, Mendel I, Raidot JP, Kandel G, De Meuter R, Fabrigli P, Dehenau D, Arroyo JL, Padron F, Gouezec H, Corral M, Jacquet M, Sundin D, Lin L, Corash L: An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008; 94:315-323.
107. Osselaer JC, Messe N, Hervig T, Bueno J, Castro E, Espinosa A, Accorsi P, Junge K, Jacquet M, Flament J, Corash L: A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008;48:1061-1071.
108. Cazenave JP, Waller C, Kientz D, Mendel I, Lin L, Jacquet M, Propst M, Liu W, Corash L, Sundin D, Defoin L, Messe N, Osselaer JC: An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion 2010;50:1210-1219.
109. Cazenave JP, Follea G, Bardiaux L, Boiron JM, Lafeuillade B, Debost M, Lioure B, Harousseau JL, Deconinck E, Tabrizi R, Cahn JY, Michallet M, Ambruso D, Tissot JD, Sensebe L, Kondo T, McCullough J, Rebulla P, Escolar G, Mintz P, Heddle NM, Goodrich RP, Bruhwyler J, Le C, Cook RJ, Stouch B, Fletcher D, Deberdt L; Mirasol Clinical Evaluation Study Group: A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010;50:2362-2375.
110. The Trial to Reduce Alloimmunization to Platelets Study Group: Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861-1869.
111. Antic A, Stanojkovic Z, Jelic M, Stanojkovic M: Clinical efficacy of buffy coat platelets treated with riboflavin and ultraviolet light (Mirasol PRT system). Vox Sang 2011;101(suppl 1):178.
112. Yanez M, Garcia de Coca A, Medina L, Galvez FJ, Martin Vaca MC, Martinez Alvarez M, Prieto Arija L, Blanco Peris L: Clinical evaluation of platelets treated with riboflavin and UV light in the presence of platelet additive solution in thrombocytopenic patients. Vox Sang 2011;101 (suppl 1):178.
113. Coene GC, De Schrijver E, Sabot B, Deeren D, Reynaerts I, Vandekerckhove P: In vitro and in vivo evaluation of Mirasol pathogen reduction technology treated platelets stored in SSP+. Vox Sang 2011;101(suppl 1):188-189.
114. Johansson PI, Simonsen AC, Brown PN, Ostrowski SR, Deberdt L, Van Hoydonck P, Yonemura SS, Goodrich RP: A pilot study to assess the hemostatic function of pathogen-reduced platelets in patients with thrombocytopenia. Transfusion 2012;53:2043-2052.
115. Henschler, R, Seifried E, Mufti N: Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus Med Hemother 2011;38:33-42.
116. Cancelas JA, Dumont LJ, Rugg N, Szczepiorkowski ZM, Herschel L, Siegel A, Pratt PG, Worsham DN, Erickson A, Propst M, North A, Sherman CD, Mufti NA, Reed WF, Corash L: Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process. Transfusion 2011;53:529-534.
117. Benjamin RJ, McCullough J, Mintz PD, Snyder E, Spotnitz WD, Rizzo RJ, Wages D, Lin JS, Wood L, Corash L, Conlan MG: Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a phase III clinical trial in cardiac surgery patients. Transfusion 2005;45:1739-1749.
118. Mufti NA, Erickson AC, North AK, Hanson D, Sawyer L, Corash LM, Lin L: Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 2010;38:14-19.
119. North A, Ciaravino V, Mufti N, Corash L: Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment. Transfusion 2011;51: 2208-2218.
120. Goodrich RP, Doane S, Reddy HL: Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010;38:20-30.
121. Goodrich RP, Murthy KK, Doane SK, Fitzpatrick CN, Morrow LS, Arndt PA, Reddy HL, Buytaert- Hoefen, Garratty G: Evaluation of potential immune response and in vivo survival of riboflavin- ultraviolet light-treated red blood cells in baboons. Transfusion 2009b;49:64-74.
122. Okoye OT, Reddy H, Wong MD, Doane S, Resnick S, Karamanos E, Skiada D, Goodrich R, Inaba K: Large animal evaluation of the safety and efficacy of whole blood treated with Mirasol system in a diffuse, non-surgical bleeding model. Transfusion 2013;53(suppl):82A.
123. Cancelas JA, Rugg N, Fletcher D, Pratt PG, Worsham DN, Dunn SK, Marschner S, Reddy HL, Goodrich RP: In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet lighttreated whole blood. Transfusion 2011;51:1460-1468.
124. Keil SD, Rapaport R, Doane SK, Young R, Marschner S, Campbell TB: Viral reduction of intracellular HIV using the Mirasol® system for whole blood. Vox Sang 2012;103(suppl 1):144.
125. Tonnetti L, Thorp AM, Reddy HL, Goodrich RP, Leiby DA: Evaluation of the reduction of T. cruzi with the Mirasol® system for whole blood. Transfusion 2010;50(suppl):209A.
126. Tonnetti L, Thorp AM, Reddy HL, Keil SD, Goodrich RP, Leiby DA: Evaluation of Babesia microti reduction with the Mirasol® system for whole blood. Transfusion 2011;51(suppl):27A.
127. Tonnetti L, Thorp AM, Reddy HL, Keil SD, Doane S, Goodrich RP, Leiby DA: Validating the Mirasol® system for whole blood: impact on Leishmania donovani infectivity. Transfusion 2012;52(suppl):212A.
128. Doane S, Keil SD, Gilmour H, Reddy H, Wilkinson S, Hovenga N, Goodrich R: Treatment of whole blood with riboflavin and UV light: effectiveness against clinically relevant bacterial contamination. Transfusion 2013;53(suppl):203A.
129. El Chaar ME, Atwal S, Freimanis GL, Dinko B, Sutherland CJ, Allain J-P: Inactivation of Plasmodium falciparum in whole blood by riboflavin plus irradiation. Transfusion 2013:53:3174-3183.
130. Reddy HL, Doane SK, Keil SD, Marschner S, Goodrich RP: Development of a riboflavin and ultraviolet light-based device to treat whole blood. Transfusion 2013;53(suppl):131S-136S.
131. Fast LD, Nevola M, Tavares J, Reddy HL, Goodrich RP, Marschner S: Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease? Transfusion 2013;53:373-381.
132. Owusu-Ofori S, Owusu-Ofori A, Freimanis G, Keil SD, Allain J: Riboflavin and UV illumination treatment of whole blood units in a Ghanaian blood center. Transfusion 2013;53(suppl): 202A-203A.
133. Oei W, Janssen MP, van der Poel CL, van Steenbergen JE, Rehmet S, Kretzschmar ME: Modeling the transmission risk of emerging infectious diseases through blood transfusion. Transfusion 2013;53:1421-1428.
134. Stormer M, Vollmer T, Kleesiek K, Dreier J: Spore-forming organisms in platelet concentrates: a challenge in transfusion bacterial safety. Transfus Med 2008;18:371-376.